TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Solubility and pH Compatibility Most lyophilized (freeze-dried) peptides are designed to be reconstituted with a slightly acidic diluent
Moir, R
Both injected before bed
A 2022 editorial review by Sikiric and colleagues in World Journal of Gastroenterology synthesized prior rat work on major vessel occlusion, Pringle-maneuver ischemia-reperfusion, and Budd-Chiari syndrome, framing collateral-vessel recruitment as a proposed mechanism by which BPC-157 may compensate for occluded flow a narrative synthesis that does not itself report original effect sizes or p-values
Healing Injuries: Stem cell therapy can accelerate the healing process for shoulder joint injuries, including those affecting the rotator cuff, tendons, and cartilage
